Patents by Inventor Nanshan ZHONG

Nanshan ZHONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10537601
    Abstract: The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: January 21, 2020
    Assignee: MACAU UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Jing-Rong Wang, Zhi-Hong Jiang, Qi-Tong Feng, Guo-Yuan Zhu, Wei-Na Gao, Zifeng Yang, Nanshan Zhong
  • Patent number: 10485773
    Abstract: Provided are benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof. Also provided is a method for treating cancer by using a pharmaceutical composition including the benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof and pharmaceutically acceptable carriers.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: November 26, 2019
    Assignee: GONGWIN BIOPHARM HOLDINGS CO., LTD.
    Inventors: Chuan-Ching Yang, Shun-Chi Wu, Nanshan Zhong, Mao-Yuan Lin, Chi-Chiang Tu, On Lee
  • Publication number: 20190321313
    Abstract: Provided are benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof. Also provided is a method for treating cancer by using a pharmaceutical composition including the benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof and pharmaceutically acceptable carriers.
    Type: Application
    Filed: June 28, 2019
    Publication date: October 24, 2019
    Inventors: Chuan-Ching YANG, Shun-Chi WU, Nanshan ZHONG, Mao-Yuan LIN, Chi-Chiang TU
  • Patent number: 10251854
    Abstract: Disclosed are an S-(carboxymethyl)-cysteine pharmaceutical compound (I), and a preparation method and use thereof. Also disclosed are an S-(carboxymethyl)-D-cysteine ammonium salt monohydrate, and use thereof in preparation of medicines for preventing and treating respiratory system diseases such as chronic obstructive pulmonary diseases, in particular in preparation of expectorants. The compounds can reduce airway resistance and production of oxides in rat COPD models, increase the level of antioxidants, and alleviate damage caused by the oxides and inflammatory mediators to lungs.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: April 9, 2019
    Assignees: Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., Baiyunshan Pharmaceutical General Factroy Guangzhou Institute of Respiratory Disease
    Inventors: Mao Chen, Shaoxuan Zhu, Ping Wan, Wei Wang, Wei Liao, Hairong Hu, Xianglin Fu, Jin Feng, Binge Huang, Lin Zhang, Nanshan Zhong, Jinping Zheng, Hongying Mo
  • Publication number: 20180311190
    Abstract: Provided are benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof. Also provided is a method for treating cancer by using a pharmaceutical composition including the benzenesulfonamide derivatives or pharmaceutically acceptable salts thereof and pharmaceutically acceptable carriers.
    Type: Application
    Filed: June 21, 2018
    Publication date: November 1, 2018
    Inventors: Chuan-Ching YANG, Shun-Chi WU, Nanshan ZHONG, Mao-Yuan LIN, Chi-Chiang TU
  • Publication number: 20180055796
    Abstract: A pharmaceutical composition exhibiting anti-tumor activity is provided. The pharmaceutical composition comprises para-toluenesulfonamide (PTS) and a pharmaceutically acceptable carrier. The pharmaceutical composition is used for treating squamous-cell carcinoma. The present invention further provides a method for treating a patient suffering from cancer and a method for inhibiting tumor growth.
    Type: Application
    Filed: August 23, 2016
    Publication date: March 1, 2018
    Inventors: NANSHAN ZHONG, LONGJIANG LI, Chia-Shun Shih, LESTER J. Wu, Mao-Yuan Lin
  • Publication number: 20170333374
    Abstract: Disclosed are an S-(carboxymethyl)-cysteine pharmaceutical compound (I), and a preparation method and use thereof. Also disclosed are an S-(carboxymethyl)-D-cysteine ammonium salt monohydrate, and use thereof in preparation of medicines for preventing and treating respiratory system diseases such as chronic obstructive pulmonary diseases, in particular in preparation of expectorants. The compounds can reduce airway resistance and production of oxides in rat COPD models, increase the level of antioxidants, and alleviate damage caused by the oxides and inflammatory mediators to lungs.
    Type: Application
    Filed: July 5, 2013
    Publication date: November 23, 2017
    Applicants: Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., Baiyunshan Pharmaceutical General Factory, Guangzhou Institute of Respiratory Disease
    Inventors: Mao Chen, Shaoxuan Zhu, Ping Wan, Wei Wang, Wei Liao, Hairong Hu, Xianglin Fu, Jin Feng, Binge Huang, Lin Zhang, Nanshan Zhong, Jinping Zheng, Hongying Mo
  • Patent number: 9782370
    Abstract: Provided is a method for treating adenoid cystic carcinoma by using a pharmaceutical composition including benzenesulfonamide derivatives and pharmaceutically acceptable carriers.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: October 10, 2017
    Assignee: Gongwin Biopharm Holdings Co., Ltd.
    Inventors: Chuan-Ching Yang, Nanshan Zhong, Mao-Yuan Lin, Chi-Chiang Tu, Kun-Hung Chen, Chia-Yen Hsiao
  • Publication number: 20170281702
    Abstract: The present invention provides a method of isolating at least one ingredient with anti-viral efficacy from Baphicacanthus cusia. The ingredient can be an alkaloid, a triterpenoid, a lignan, a phenylethanoid, a sesquiterpene lactone, or a flavonoid. Two new alkaloids are produced, which have not been previously reported. Moreover, the method isolates 12 compounds which could not or have not been previously isolated. A pharmaceutical composition includes the at least one ingredient and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from a viral disease includes administering at least one ingredient isolated from Baphicacanthus cusia.
    Type: Application
    Filed: April 4, 2016
    Publication date: October 5, 2017
    Inventors: Jing-Rong Wang, Zhi-Hong Jiang, Qi-Tong Feng, Guo-Yuan Zhu, Wei-Na Gao, Zifeng Yang, Nanshan Zhong
  • Publication number: 20170172951
    Abstract: Provided is a method for treating adenoid cystic carcinoma by using a pharmaceutical composition including benzenesulfonamide derivatives and pharmaceutically acceptable carriers.
    Type: Application
    Filed: December 21, 2016
    Publication date: June 22, 2017
    Inventors: Chuan-Ching YANG, Nanshan ZHONG, Mao-Yuan LIN, Chi-Chiang TU, Kun-Hung CHEN, Chia-Yen HSIAO
  • Patent number: 9629869
    Abstract: The present invention relates to a new application of Fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals for treating coughing, and more specifically to a new application of Fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals for preventing and relieving coughing and eliminating airway inflammation. Experiments demonstrate that the Fructus schisandrae total polysaccharides can remarkably reduce the coughing times of a guinea pig with increased cough sensitivity induced by cigarette smoke and an acute cough guinea pig induced by citric acid smoke, prolong the latent period of cough, and significantly reduce the airway inflammation of the guinea pig with increased cough susceptibility induced by cigarette smoke, so that the Fructus schisandrae total polysaccharides can be used for preparing drugs for preventing cough, relieving cough and eliminating airway inflammation.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: April 25, 2017
    Inventors: Kefang Lai, Shan Zhong, Zhenyong Gan, Xiaodong Liu, Yichu Nie, Nanshan Zhong
  • Publication number: 20170056431
    Abstract: The present invention relates to a new application of Fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals for treating coughing, and more specifically to a new application of Fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals for preventing and relieving coughing and eliminating airway inflammation. Experiments demonstrate that the Fructus schisandrae total polysaccharides can remarkably reduce the coughing times of a guinea pig with increased cough sensitivity induced by cigarette smoke and an acute cough guinea pig induced by citric acid smoke, prolong the latent period of cough, and significantly reduce the airway inflammation of the guinea pig with increased cough susceptibility induced by cigarette smoke, so that the Fructus schisandrae total polysaccharides can be used for preparing drugs for preventing cough, relieving cough and eliminating airway inflammation.
    Type: Application
    Filed: November 15, 2016
    Publication date: March 2, 2017
    Inventors: Kefang Lai, Shan Zhong, Zhenyong Gan, Xiaodong Liu, Yichu Nie, Nanshan Zhong
  • Publication number: 20130259809
    Abstract: A process of using Isatis root polysaccharide in the manufacture of medicaments for treating and/or preventing diseases induced by influenza virus and complications thereof, wherein the molecular weight of the Isatis root polysaccharide is 3000-7000 Da, and the influenza viruses include influenza virus A, influenza virus B, avian influenza virus, such as human influenza virus H1N1, H3N2, avian influenza virus H6N2, H7N3, H9N2 and INF B. The mechanism of the Isatis root polysaccharide against influenza virus is due to the ability to inhibit the attachment of influenza virus to the host cell. The present invention also discloses a pharmaceutical composition containing the above-mentioned Isatis root polysaccharides and a method for preparing the polysaccharides.
    Type: Application
    Filed: April 9, 2013
    Publication date: October 3, 2013
    Inventors: Zifeng YANG, Chuyuan LI, Yutao WANG, Suishan ZHAO, Nanshan ZHONG, Qing LIN, Zheng WANG, Sheng QIN, Wenda GUAN, Ziyao MO, Deqin WANG